JNJ

192.06

-0.32%↓

ABT

126.47

-1.09%↓

MDT

94.35

-1.76%↓

VEEV

291.35

+0.66%↑

A

147.16

+0.91%↑

JNJ

192.06

-0.32%↓

ABT

126.47

-1.09%↓

MDT

94.35

-1.76%↓

VEEV

291.35

+0.66%↑

A

147.16

+0.91%↑

JNJ

192.06

-0.32%↓

ABT

126.47

-1.09%↓

MDT

94.35

-1.76%↓

VEEV

291.35

+0.66%↑

A

147.16

+0.91%↑

JNJ

192.06

-0.32%↓

ABT

126.47

-1.09%↓

MDT

94.35

-1.76%↓

VEEV

291.35

+0.66%↑

A

147.16

+0.91%↑

JNJ

192.06

-0.32%↓

ABT

126.47

-1.09%↓

MDT

94.35

-1.76%↓

VEEV

291.35

+0.66%↑

A

147.16

+0.91%↑

Search

Crinetics Pharmaceuticals Inc

Open

SectorGezondheidszorg

40.19 -0.64

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

39.79

Max

41.05

Belangrijke statistieken

By Trading Economics

Inkomsten

-19M

-116M

Verkoop

670K

1M

Winstmarge

-11,216.004

Werknemers

437

EBITDA

-19M

-129M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+99.36% upside

Dividenden

By Dow Jones

Volgende Winsten

6 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.4B

4B

Vorige openingsprijs

40.83

Vorige sluitingsprijs

40.19

Nieuwssentiment

By Acuity

50%

50%

168 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 okt 2025, 22:47 UTC

Acquisities, Fusies, Overnames

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project -- Update

22 okt 2025, 22:13 UTC

Acquisities, Fusies, Overnames

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project

22 okt 2025, 21:20 UTC

Winsten

Correction to IBM 3Q Sales Jump Article

22 okt 2025, 20:57 UTC

Winsten

SAP Posts Higher 3Q Revenue, Operating Profit

22 okt 2025, 23:46 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

22 okt 2025, 23:46 UTC

Marktinformatie

Nikkei May Decline Amid U.S.-China Trade Tensions -- Market Talk

22 okt 2025, 23:41 UTC

Marktinformatie

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 okt 2025, 23:38 UTC

Marktinformatie

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 okt 2025, 23:15 UTC

Winsten

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 4th Update

22 okt 2025, 22:28 UTC

Marktinformatie

Alcoa Cautions About Spending More on U.S. Smelters -- Market Talk

22 okt 2025, 22:02 UTC

Winsten

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 3rd Update

22 okt 2025, 21:59 UTC

Acquisities, Fusies, Overnames

Williams Cos.: Entered Into 1.5 Mtpa LNG Offtake Obligation >WMB

22 okt 2025, 21:58 UTC

Acquisities, Fusies, Overnames

Williams Cos. to Buy 10% Interest in Louisiana LNG LLC >WMB

22 okt 2025, 21:57 UTC

Acquisities, Fusies, Overnames

Williams Cos. to Buy 80% Ownership In, Become Operator of Driftwood Pipeline >WMB

22 okt 2025, 21:56 UTC

Acquisities, Fusies, Overnames

Williams Cos.: Strategic Partnership Entered With Woodside Energy to Invest in Louisiana LNG Project >WMB

22 okt 2025, 21:47 UTC

Acquisities, Fusies, Overnames

Woodside: Williams to Assume LNG Offtake Obligations for 10% of Produced Volumes

22 okt 2025, 21:47 UTC

Winsten

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 okt 2025, 21:47 UTC

Acquisities, Fusies, Overnames

Woodside: Williams to Contribute Its Share of Capex for LNG Facility, Pipeline

22 okt 2025, 21:46 UTC

Acquisities, Fusies, Overnames

Woodside Energy Says Williams Deals Worth US$378 Million Including Capital Reimbursement

22 okt 2025, 21:45 UTC

Acquisities, Fusies, Overnames

Woodside Energy to Sell 80% Interest in Driftwood Pipeline Co. to Williams

22 okt 2025, 21:45 UTC

Acquisities, Fusies, Overnames

Woodside Energy to Sell 10% Interest in Louisiana LNG Holding Co. to Williams

22 okt 2025, 21:28 UTC

Marktinformatie
Winsten

Correction to Alcoa Tariff Market Talk

22 okt 2025, 21:25 UTC

Winsten

Wall Street Wonders if Grail's Cancer Test Results Are a True Positive -- Barrons.com

22 okt 2025, 21:17 UTC

Winsten

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 2nd Update

22 okt 2025, 21:09 UTC

Marktinformatie
Winsten

Alcoa Says Delivery Fee Covering Tariff Costs -- Market Talk

22 okt 2025, 21:00 UTC

Marktinformatie

ESG Roundup: Market Talk

22 okt 2025, 20:59 UTC

Winsten

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 okt 2025, 20:51 UTC

Winsten

SAP Reports Mixed Earnings. The Stock is Down. -- Barrons.com

22 okt 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

22 okt 2025, 20:44 UTC

Winsten

Kaiser Aluminum: For the Full Yr 2025, Now Expects Conversion Rev to Be Flat to Up 5% Yr-Over-Yr and Raises Adjusted EBITDA Outlook to Improve 20% to 25% Yr-Over-Yr >KALU

Peer Vergelijking

Prijswijziging

Crinetics Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

99.36% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 80.6 USD  99.36%

Hoogste 143 USD

Laagste 40 USD

Gebaseerd op 16 Wall Street-analisten die 12-maands prijsdoelen bieden voor Crinetics Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

16 ratings

15

Buy

1

Hold

0

Sell

Technische score

By Trading Central

30.39 / 33.46Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Neutral Evidence

Sentiment

By Acuity

168 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat